Phase 2/3CompletedAge-related condition
Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid (BRAVE-EPA)
Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults
- Sponsor
- VA Office of Research and Development (US federal)
- Enrollment
- 131 enrolled
- Conditions
- Alzheimer's Disease
- Interventions
- icosapent ethyl (IPE); gel cap placebo
- Ages
- adults, older adults
- Registry
- NCT02719327
Full record on ClinicalTrials.gov
From the registry
The number of Americans diagnosed with Alzheimer's disease (AD) is expected to triple by 2050. Compared to the general population, Veterans have a greater risk of AD, likely in part due to their increased incidence of traumatic brain injury, post-traumatic stress disorder, depression, and other vascular-related health issues. Based on available data, 423,000 new cases of AD are anticipated in Veterans by 2020. Thus, the discovery of effective therapies to prevent or delay the onset of AD in Veterans is critical. The goal of this study is to evaluate the efficacy of a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) called icosapent ethyl (IPE), on improving brain blood flow, spinal fluid markers of AD pathology, and cognitive performance in middle-aged, cognitively-healthy Veterans with increased risk of AD. If IPE delays the onset of AD by even 5 years, the incidence of AD would be reduced by 50% in this population and could have a profound effect on Veteran quality of life and healthcare costs.
Primary outcomes
- Regional Cerebral Blood Flow Using Arterial Spin-labeling MRI
History
Results first posted
Last registry update
Primary completion
Started
Registered
Papers citing this trial
- Protein links to Alzheimer’s markers differ by gene variant
Neurobiology of disease
- Assessing the effect of eicosapentaenoic acid (EPA) on CSF levels of matrix metalloproteinases and their inhibitors
AAIC 2025 abstract
- Impact of icosapent ethyl on CSF NULISA vascular, metabolic, and AD biomarkers in cognitively unimpaired Veterans at risk for dementia
AAIC 2025 abstract
- Distinct Roles of MMP‐9 and CX3CL1 on ptau217 and β‐Amyloid Levels in APOE4 Carriers versus Noncarriers
AAIC 2025 abstract